1. Chemotherapy and other treatments can destroy immune cells, leading to potentially deadly infections in cancer patients with weakened immune systems. 2. Leuko is developing an at-home white blood cell monitor that uses light and artificial intelligence to detect dangerously low white blood cell levels without drawing blood. 3. The technology was conceived by MIT researchers in 2015, and Leuko's devices have accurately detected low white blood cell counts in hundreds of cancer patients. 4. The company has been working with the FDA to confirm the accuracy and ease of use of their device, expecting to begin a pivotal study for FDA approval later this year. 5. Leuko's team believes the device could optimize cancer treatment by personalizing chemotherapy doses based on individual patient reactions. 6. The device could also be used to monitor immune health in other patient populations, such as those with multiple sclerosis, autoimmune diseases, organ transplants, and emergency room patients. 7. The company envisions the device as a platform technology for measuring other blood parameters beyond white blood cells in the future.